A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)
Clinical trial NCT04062448 · COMPLETED
Trial details
- NCT number
- NCT04062448
- Sponsor
- Janssen Pharmaceutical K.K.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-25
- Primary completion
- 2021-08-24
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.